GLP-1 drugs may be hailed as a medical breakthrough in obesity care, but Indian experts warn they are no cosmetic quick-fix.

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

Semaglutide, a popular anti-obesity drug, may come with a hidden cost: significant muscle loss, especially in women and older adults. A small study found that up to 40% of weight loss from semaglutide ...

Medications such as Ozempic and Saxenda have grown in popularity due to their ability to treat type 2 diabetes and assist in weight loss. These medications belong to a class of drugs known as GLP-1 ...

Among patients receiving semaglutide for obesity management, the risk for muscle loss may be higher in older adults and women ...

There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

Lotte Bjerre Knudsen, Chief Scientific Adviser for Research at Danish pharma giant Novo Nordisk, speaks about GLP-1-based ...

Cheaper versions of medications to treat obesity, like Ozempic and Wegovy, could be on the market in Canada as soon as ...

WEIGHT loss jabs could boost men’s sex lives, a study suggests. Research found injections like Wegovy and Mounjaro can raise ...

Experts are warning people using weight-loss jabs could be invalidating travel insurance if they fail to declare the ...

Research indicates GLP-1 receptor agonists, like Ozempic, may elevate testosterone levels in men while promoting weight loss.

Combining ASC47 with semaglutide, the new therapy aims to reshape obesity treatment with targeted, once-monthly injections.